Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system designed to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which are comprised of sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology Inc.

In a report released today, from Guggenheim reiterated a Buy rating on Nautilus Biotechnolgy, with a price target of $2.50. The word on The Street ...

Market Cap	$194.51M	P/E Ratio	NaN
52W High	$2.54	52W Low	$0.62
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-6.8%	52W Position	64.1%
Overall Score	48	Value Score	60
Quality Score	26	Technical Score	58

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAUT	$1.85	-6.57%	247.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NAUT	$1.85	-6.6%	247.13K
3
4
5
6

NAUT

NAUT

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Nautilus Biotechnology Inc. Data in Excel

Get Nautilus Biotechnology Inc. Data in Excel